Evidence map›Paper›PMID 22902361›Full record

ArticleLeukemia2013

The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.

C Fialin, C Larrue, F Vergez, J E Sarry, S Bertoli, V Mansat-De Mas, C Demur, E Delabesse, B Payrastre, S Manenti and 2 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?International journal of molecular sciences · 2019
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

C FialinINSERM UMR1037-Cancer Research Center of Toulouse, CNRS ERL 5294, Pavillon Lefebvre BP3028, CHU Purpan, Toulouse, France.
C Larrue
F Vergez
J E Sarry
S Bertoli
V Mansat-De Mas
C Demur
E Delabesse
B Payrastre
S Manenti
S Roche
C Récher
Centre de Recherche en Cancérologie de Toulouse · FRCentre National de la Recherche Scientifique · FRHôpital Purpan · FRCentre Hospitalier Universitaire de Toulouse · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several receptor tyrosine kinases (TKs) are involved in the pathogenesis of acute myeloid leukemia (AML). Here, we have assessed the expression of the Recepteur d'Origine Nantais (RON) in leukemic cell lines and samples from AML patients. In a series of 86 AML patients, we show that both the full length and/or the short form (sf) of RON are expressed in 51% and 43% of cases, respectively. Interestingly, sfRON is not expressed in normal CD34+ hematopoietic cells and induces part of its oncogenic signaling through interaction with the Src kinase Lyn. sfRON-mediated signaling in leukemic cells also involves mTORC1, the proapoptotic bcl2-family member, BAD, but not the phosphatidylinositol 3-kinase/Akt pathway. Furthermore, the expression of sfRON was specifically downregulated by 5-azacytidine (AZA). Conversely, AZA could induce the expression of sfRON in sfRON-negative leukemic cells suggesting that the activity of this drug in AML and myelodysplastic syndromes could involve modulation of TKs. cMET/RON inhibitors exhibited an antileukemic activity exclusively in AML samples and cell lines expressing sfRON. These results might support clinical trials evaluating cMET/RON inhibitors in AML patients expressing sfRON.

Indexed as

AdolescentAdultAgedAged, 80 and overAntimetabolites, AntineoplasticApoptosisAzacitidinebcl-Associated Death ProteinBlotting, WesternCell ProliferationCells, CulturedDrug Resistance, NeoplasmFemaleFlow CytometryHematopoietic Stem CellsHumans((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)Antimetabolites, AntineoplasticAzacitidineBAD protein, humanbcl-Associated Death ProteinIndoleslyn protein-tyrosine kinaseMechanistic Target of Rapamycin Complex 1MET protein, humanMultiprotein ComplexesPhosphatidylinositol 3-KinasesPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metReceptor Protein-Tyrosine KinasesRNA, MessengerRNA, Small InterferingRON proteinsrc-Family KinasesSulfonamidesTOR Serine-Threonine Kinases

Identifiers

PMID22902361
OpenAlexW2013316377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.